(2E) N-{4-[(2-tert-butylaminosulfonyl)phenyl]-2-fluorophenyl}-3-(isoquinolin-7-yl)-2-fluoro-3-methylacrylamide | 288309-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2E) N-{4-[(2-tert-butylaminosulfonyl)phenyl]-2-fluorophenyl}-3-(isoquinolin-7-yl)-2-fluoro-3-methylacrylamide
• 英文别名: (E)-N-[4-[2-(tert-butylsulfamoyl)phenyl]-2-fluorophenyl]-2-fluoro-3-isoquinolin-7-ylbut-2-enamide
• CAS: 288309-12-6
• 化学式: C₂₉H₂₇F₂N₃O₃S
• 分子量: 535.614
• InChiKey: RWXHAPDOCBAEDQ-OVVQPSECSA-N

物化性质

• 密度：
  1.295±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  96.5
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (2E) N-{4-[(2-tert-butylaminosulfonyl)phenyl]-2-fluorophenyl}-3-(isoquinolin-7-yl)-2-fluoro-3-methylacrylamide 在 间氯过氧苯甲酸 作用下， 以 丙酮 为溶剂， 生成
  参考文献：
  名称：

  Substituted acrylamides as factor Xa inhibitors: improving bioavailability by P1 modification

  摘要：

  To overcome the low bioavailability of our substituted acrylamide P1 benzamidine factor Xa inhibitors reported previously, neutral and less basic groups were used to replace the benzamidine. As a result, a series of P1 aminoisoquinoline substituted acrylamide Xa inhibitors was identified to be potent, selective, and orally bioavailable. Modification of P4 moiety of these compounds further improved their pharmacokinetic properties. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00304-9
• 作为产物：
  描述：

  N-[(3-溴苯基)亚甲基]-2,2-二甲氧基乙胺 在 三甲基铝 作用下， 以 二氯甲烷 为溶剂， 生成 (2E) N-{4-[(2-tert-butylaminosulfonyl)phenyl]-2-fluorophenyl}-3-(isoquinolin-7-yl)-2-fluoro-3-methylacrylamide
  参考文献：
  名称：

  Substituted acrylamides as factor Xa inhibitors: improving bioavailability by P1 modification

  摘要：

  To overcome the low bioavailability of our substituted acrylamide P1 benzamidine factor Xa inhibitors reported previously, neutral and less basic groups were used to replace the benzamidine. As a result, a series of P1 aminoisoquinoline substituted acrylamide Xa inhibitors was identified to be potent, selective, and orally bioavailable. Modification of P4 moiety of these compounds further improved their pharmacokinetic properties. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00304-9

文献信息

• Inhibitors of factor Xa
  申请人：Cor Therapeutics, Inc.

  公开号：US06399627B1

  公开（公告）日：2002-06-04

  Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

  披露了新型化合物、它们的盐和与它们相关的组合物，这些化合物对哺乳动物因子Xa具有活性。这些化合物在体外或体内用于预防或治疗凝血障碍。